Switch to
View more

Cipla Ltd

CIPLA
Health CarePharmaceuticals
LargecapWith a market cap of ₹86,195 cr, stock is ranked 62
Low RiskStock is 1.40x as volatile as Nifty
1,068.106.20 (+0.58%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
LargecapWith a market cap of ₹86,195 cr, stock is ranked 62
Low RiskStock is 1.40x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
34.25
PB RatioPB Ratio
4.08
Dividend YieldDiv. Yield
0.47%
Sector PESector PE
34.43
Sector PBSector PB
4.21
Sector Div YldSctr Div Yld
0.93%

Forecast & RatingsDetailed Forecast 

79%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Cipla Limited is a pharmaceutical company. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology & cosmetology, diabetes, HIV/AIDS, infectious diseases & critical care, malaria etc.

Brands

Cipla

Pharmaceutical company

Investor PresentationView older 

Jul 29, 2022

PDF
View Older Presentations

Brands

Cipla

Pharmaceutical company

Financial TrendFinancial statements 

201920202021202216.8417.4819.4322.041.531.552.402.52
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 2.49%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

General updates 
Announced OnSep 22, 2022

Cipla Limited has informed the Exchange about Closure of US FDA product-specific Pre-Approval Inspection | Download

Cipla Limited has informed the Exchange about Closure of US FDA product-specific Pre-Approval Inspection | Download

ESOP/ESPS/SBEB Scheme 
Announced OnSep 14, 2022

Cipla Limited has informed the Exchange about allotment of 5,683 equity shares under ESOS 2013-A Scheme and Cipla ESAR Scheme 2021 of the Company | Download

Cipla Limited has informed the Exchange about allotment of 5,683 equity shares under ESOS 2013-A Scheme and Cipla ESAR Scheme 2021 of the Company | Download

Cash Dividend 
Ex. DateAug 8, 2022

Final • Div/Share: ₹ 5

See all events